Early Detection of Lung Cancer: Metabolic Biomarkers for High Risk Screening (MEDLUNG) View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2008-

ABSTRACT

RATIONALE: Collecting and storing samples of sputum and tissue to study in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking samples of sputum and tissue from lung cancer patients, participants at high risk for developing lung cancer, and from healthy volunteers (both smokers and non-smokers). Detailed Description OBJECTIVES: - To test and make a preliminary assessment of the sensitivity and specificity of Fourier transform infrared technology (FTIR) for use in the early detection of lung cancer in sputum samples from patients who have or participants at high risk for developing lung cancer and from non-high-risk smoking and non-smoking volunteers. - To permit identification of specific metabolic biomarkers within FTIR spectra that can distinguish between lung cancer, high-risk, and non-high-risk cases. OUTLINE: This is a multicenter study. Sputum samples and endobronchial biopsy tissue specimens are collected prior to routine bronchoscopy as part of a standard clinical assessment for the early detection of lung cancer. Sputum samples are examined for levels of bronchial and non-bronchial cells using established cytological and immunohistochemical procedures. Samples are also examined for metabolic biomarkers using Fourier transform infrared spectroscopy (FTIR) to generate complete metabolic fingerprints (i.e., spectra) that can distinguish metabolic differences between cancer, non-cancer, and early disease (i.e., dysplasia or metaplasia). These molecular biomarkers, which are detected within FTIR spectra, may be further analyzed in matched endobronchial biopsy tissue samples for histological confirmation. Additional clinico-pathological data is collected for each participant to allow development of predictive statistical models from the data. All study participants are followed annually. More... »

URL

https://clinicaltrials.gov/show/NCT00899262

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "RATIONALE: Collecting and storing samples of sputum and tissue to study in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking samples of sputum and tissue from lung cancer patients, participants at high risk for developing lung cancer, and from healthy volunteers (both smokers and non-smokers).\n\nDetailed Description\nOBJECTIVES: - To test and make a preliminary assessment of the sensitivity and specificity of Fourier transform infrared technology (FTIR) for use in the early detection of lung cancer in sputum samples from patients who have or participants at high risk for developing lung cancer and from non-high-risk smoking and non-smoking volunteers. - To permit identification of specific metabolic biomarkers within FTIR spectra that can distinguish between lung cancer, high-risk, and non-high-risk cases. OUTLINE: This is a multicenter study. Sputum samples and endobronchial biopsy tissue specimens are collected prior to routine bronchoscopy as part of a standard clinical assessment for the early detection of lung cancer. Sputum samples are examined for levels of bronchial and non-bronchial cells using established cytological and immunohistochemical procedures. Samples are also examined for metabolic biomarkers using Fourier transform infrared spectroscopy (FTIR) to generate complete metabolic fingerprints (i.e., spectra) that can distinguish metabolic differences between cancer, non-cancer, and early disease (i.e., dysplasia or metaplasia). These molecular biomarkers, which are detected within FTIR spectra, may be further analyzed in matched endobronchial biopsy tissue samples for histological confirmation. Additional clinico-pathological data is collected for each participant to allow development of predictive statistical models from the data. All study participants are followed annually.", 
    "id": "sg:clinicaltrial.NCT00899262", 
    "keywords": [
      "metabolic biomarkers", 
      "rationale", 
      "collecting", 
      "storing", 
      "sputum", 
      "tissue", 
      "laboratory", 
      "doctor", 
      "Biological Marker", 
      "Neoplasm", 
      "research study", 
      "sample", 
      "lung cancer patient", 
      "high risk", 
      "Lung Neoplasm", 
      "healthy volunteer", 
      "smoker", 
      "non-smokers", 
      "preliminary assessment", 
      "Fourier Transform Infrared Spectroscopy", 
      "early detection", 
      "sputum sample", 
      "patient", 
      "non-smoking", 
      "spectrum", 
      "high-risk case", 
      "outline", 
      "multicenter study", 
      "tissue specimen", 
      "bronchoscopy", 
      "clinical assessment", 
      "cell", 
      "infrared spectroscopy", 
      "metabolic difference", 
      "non-cancer", 
      "early disease", 
      "dysplasia", 
      "metaplasia", 
      "molecular biomarkers", 
      "biopsy tissue", 
      "confirmation", 
      "development", 
      "statistical model", 
      "study participant"
    ], 
    "name": "Early Detection of Lung Cancer: Metabolic Biomarkers for High Risk Screening (MEDLUNG)", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00899262"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00007.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.48336.3a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.415947.a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.4827.9", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.415213.0", 
        "type": "Organization"
      }
    ], 
    "startDate": "2008-04-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/1471-2407-10-640", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049943720", 
          "https://doi.org/10.1186/1471-2407-10-640"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00899262"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00899262'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00899262'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00899262'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00899262'


 

This table displays all metadata directly associated to this object as RDF triples.

72 TRIPLES      15 PREDICATES      62 URIs      52 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00899262 schema:about anzsrc-for:3142
2 schema:description RATIONALE: Collecting and storing samples of sputum and tissue to study in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking samples of sputum and tissue from lung cancer patients, participants at high risk for developing lung cancer, and from healthy volunteers (both smokers and non-smokers). Detailed Description OBJECTIVES: - To test and make a preliminary assessment of the sensitivity and specificity of Fourier transform infrared technology (FTIR) for use in the early detection of lung cancer in sputum samples from patients who have or participants at high risk for developing lung cancer and from non-high-risk smoking and non-smoking volunteers. - To permit identification of specific metabolic biomarkers within FTIR spectra that can distinguish between lung cancer, high-risk, and non-high-risk cases. OUTLINE: This is a multicenter study. Sputum samples and endobronchial biopsy tissue specimens are collected prior to routine bronchoscopy as part of a standard clinical assessment for the early detection of lung cancer. Sputum samples are examined for levels of bronchial and non-bronchial cells using established cytological and immunohistochemical procedures. Samples are also examined for metabolic biomarkers using Fourier transform infrared spectroscopy (FTIR) to generate complete metabolic fingerprints (i.e., spectra) that can distinguish metabolic differences between cancer, non-cancer, and early disease (i.e., dysplasia or metaplasia). These molecular biomarkers, which are detected within FTIR spectra, may be further analyzed in matched endobronchial biopsy tissue samples for histological confirmation. Additional clinico-pathological data is collected for each participant to allow development of predictive statistical models from the data. All study participants are followed annually.
3 schema:keywords Biological Marker
4 Fourier Transform Infrared Spectroscopy
5 Lung Neoplasm
6 Neoplasm
7 biopsy tissue
8 bronchoscopy
9 cell
10 clinical assessment
11 collecting
12 confirmation
13 development
14 doctor
15 dysplasia
16 early detection
17 early disease
18 healthy volunteer
19 high risk
20 high-risk case
21 infrared spectroscopy
22 laboratory
23 lung cancer patient
24 metabolic biomarkers
25 metabolic difference
26 metaplasia
27 molecular biomarkers
28 multicenter study
29 non-cancer
30 non-smokers
31 non-smoking
32 outline
33 patient
34 preliminary assessment
35 rationale
36 research study
37 sample
38 smoker
39 spectrum
40 sputum
41 sputum sample
42 statistical model
43 storing
44 study participant
45 tissue
46 tissue specimen
47 schema:name Early Detection of Lung Cancer: Metabolic Biomarkers for High Risk Screening (MEDLUNG)
48 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00899262
49 schema:sdDatePublished 2019-03-07T15:23
50 schema:sdLicense https://scigraph.springernature.com/explorer/license/
51 schema:sdPublisher Nb2532d88c27240b1831bda60729c5065
52 schema:sponsor https://www.grid.ac/institutes/grid.415213.0
53 https://www.grid.ac/institutes/grid.415947.a
54 https://www.grid.ac/institutes/grid.4827.9
55 https://www.grid.ac/institutes/grid.48336.3a
56 schema:startDate 2008-04-01T00:00:00Z
57 schema:subjectOf sg:pub.10.1186/1471-2407-10-640
58 schema:url https://clinicaltrials.gov/show/NCT00899262
59 sgo:license sg:explorer/license/
60 sgo:sdDataset clinical_trials
61 rdf:type schema:MedicalStudy
62 Nb2532d88c27240b1831bda60729c5065 schema:name Springer Nature - SN SciGraph project
63 rdf:type schema:Organization
64 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
65 rdf:type schema:DefinedTerm
66 sg:pub.10.1186/1471-2407-10-640 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049943720
67 https://doi.org/10.1186/1471-2407-10-640
68 rdf:type schema:CreativeWork
69 https://www.grid.ac/institutes/grid.415213.0 schema:Organization
70 https://www.grid.ac/institutes/grid.415947.a schema:Organization
71 https://www.grid.ac/institutes/grid.4827.9 schema:Organization
72 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...